Pablo Rojas Ruz
@uro-oncology.bsky.social
Chilean Urologist. Uro-oncology. Robotic surgery. Fellow at Hospital Rey Juan Carlos, Madrid.
Excelente meta-análisis
Patient-Level Data Confirms ARPI Value in mHSPC Treatment in Meta-Analysis - David Fisher
David Fisher discusses a meta-analysis of individual patient-level data from multiple Phase III trials. The research examines which patients with metastatic hormone-sensitive prostate cancer benefit f...
www.urotoday.com
March 6, 2025 at 5:24 PM
Excelente meta-análisis
PSMA PET imaging (radioisotope independent) revolutionizes prostate cancer BCR detection, offering superior sensitivity at low PSA levels, aiding treatment decisions.
November 28, 2024 at 8:59 AM
PSMA PET imaging (radioisotope independent) revolutionizes prostate cancer BCR detection, offering superior sensitivity at low PSA levels, aiding treatment decisions.
Reposted by Pablo Rojas Ruz
Active surveillance for intermediate-risk prostate cancer rose from 5% in 2010 to 12.3% in 2020. Most common in GG1 cases (53.8% by 2020). PSA and GG remain key factors.
#ProstateCancer #ActiveSurveillance #Oncology #CancerResearch
@oncoalert.bsky.social
#ProstateCancer #ActiveSurveillance #Oncology #CancerResearch
@oncoalert.bsky.social
November 21, 2024 at 6:48 AM
Active surveillance for intermediate-risk prostate cancer rose from 5% in 2010 to 12.3% in 2020. Most common in GG1 cases (53.8% by 2020). PSA and GG remain key factors.
#ProstateCancer #ActiveSurveillance #Oncology #CancerResearch
@oncoalert.bsky.social
#ProstateCancer #ActiveSurveillance #Oncology #CancerResearch
@oncoalert.bsky.social